Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma

NCT02063685 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

807

Enrollment

OTHER

Sponsor class

Conditions

Follicular Non-Hodgkin's Lymphoma

Interventions

DRUG: R-CHOP or R-bendamustine
DRUG: Observation
DRUG: Maintenance weekly x4
DRUG: Ibritumomab Tiuxetan + Maintenance
DRUG: Standard Maintenance

Sponsor

Fondazione Italiana Linfomi - ETS